Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial
Single-Agent Trabectedin versus Chemotherapie nach Wahl der Ärztin/des Arztes bei Patient:innen mit rezidivierendem Ovarialkarzinom mit BRCA-Mutation und/oder BRCAness-Phänotyp: randomisierte Phase-III-Studie
Journal of Clinical Oncology · 01.05.2024 · 42 (13) · 1488-1498
DOI: 10.1200/jco.23.01225 ↗Auf einen Blick
Trabectedin verbesserte das Gesamtüberleben bei rezidivierendem Ovarialkarzinom mit BRCA-Mutation und/oder BRCAness nicht gegenüber Chemotherapie nach Wahl der Ärztin/des Arztes. Auch das Sicherheitsprofil war ungünstiger.
Fragestellung
Ist Trabectedin als Monotherapie bei rezidivierendem Ovarialkarzinom mit BRCA-Mutation und/oder BRCAness wirksamer und sicherer als Chemotherapie nach Wahl der Ärztin/des Arztes?
Methode
Prospektive, offene, randomisierte Phase-III-Studie MITO-23 mit Trabectedin 1,3 mg/m2 alle 3 Wochen versus Chemotherapie nach Wahl der Ärztin/des Arztes.
Ergebnisse
244 Patient:innen aus 21 MITO-Zentren wurden randomisiert (122/122). Medianes OS: 15,8 vs. 17,9 Monate (P = .304); medianes PFS: 4,9 vs. 4,4 Monate (P = .897). UAW Grad ≥3, schwere UAW und schwere arzneimittelbedingte UAW häufiger unter Trabectedin.
Schlussfolgerung der Autor:innen
Trabectedin verbesserte das mediane OS nicht und zeigte im Vergleich zur Kontrollchemotherapie ein schlechteres Sicherheitsprofil.
Kernaussagen
- Medianes OS: 15,8 vs. 17,9 Monate
- Medianes PFS: 4,9 vs. 4,4 Monate
- Mehr schwere UAW unter Trabectedin
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.05.2024. Verfasst von Domenica Lorusso und 22 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy. Hauptthemen laut MEDLINE: Trabectedin, Ovarian Neoplasms, Mutation, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Literature evidence suggests that trabectedin monotherapy is effective in patients with recurrent ovarian cancer (OC) presenting BRCA mutation and/or BRCAness phenotype. METHODS A prospective, open-label, randomized phase III MITO-23 trial evaluated the activity and safety of trabectedin 1.3 mg/m 2 given once every 3 weeks (arm A) in BRCA 1/2 mutation carriers or patients with BRCAness phenotype (ie, patients who responded to ≥two previous platinum-based treatments) with recurrent OC, primary peritoneal carcinoma, or fallopian tube cancer in comparison with physician's choice chemotherapy in the control arm (arm B; pegylated liposomal doxorubicin, topotecan, gemcitabine, once-weekly paclitaxel, or carboplatin). The primary end point was overall survival (OS) evaluated in the intention-to-treat population. RESULTS Overall, 244 patients from 21 MITO centers were randomly assigned (arm A = 122/arm B = 122). More than 70% of patients received ≥three previous chemotherapy lines and 35.7% had received a poly (ADP-ribose) polymerase inhibitor (PARPi) before enrollment. Median OS was not significantly different between the arms: arm A: 15.8 versus arm B: 17.9 months ( P = .304). Median progression-free survival was 4.9 months in arm A versus 4.4 months in arm B ( P = .897). Among 208 patients evaluable for efficacy, the objective response rate was 17.1% in arm A and 21.4% in arm B, with comparable median duration of response (5.62 v 5.66 months, respectively). No superior effect was observed for trabectedin in the prespecified subgroup analyses according to BRCA mutational status, chemotherapy type, and pretreatment with a PARPi and/or platinum-free interval. Trabectedin showed a higher frequency of grade ≥3 adverse events (AEs), serious AEs, and serious adverse drug reactions compared with control chemotherapy. CONCLUSION Trabectedin did not improve median OS and showed a worse safety profile in comparison with physician's choice control chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy.
- Fondazione IRCCS Istituto Nazionale Tumori Milan, Milan, Italy.
- Department of Oncology, Oncology Unit, University of Turin, Ordine Mauriziano Hospital, Turin, Italy.
- European Institute of Oncology IRCCS and Università degli Studi di Milano Bicocca, Milan, Italy.
- Department of Urology and Gynecology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, Naples, Italy.
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, Unit of Obstetrics and Gynecology, University of Pavia, IRCCS San Matteo Hospital Foundation, Pavia, Italy.
ORCID-Profile: Domenica Lorusso, Giorgio Valabrega, Nicoletta Colombo, Carmela Pisano, Chiara Cassani, Germana Tognon, Serafina Mammoliti, Ugo De Giorgi, Anna Maria Mosconi, Enrico Breda, Claudia Andreetta, Antonio Frassoldati, Giovanni Scambia
Zitieren
APA
Lorusso, D., Raspagliesi, F., Ronzulli, D., Valabrega, G., Colombo, N., Pisano, C., Cassani, C., Tognon, G., Tamberi, S., Mangili, G., Mammoliti, S., De Giorgi, U., Greco, F., Mosconi, A. M., Breda, E., Artioli, G., Andreetta, C., Casanova, C., Ceccherini, R., …, & Scambia, G. (2024). Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial. Journal of Clinical Oncology, 42(13), 1488-1498. https://doi.org/10.1200/jco.23.01225
Vancouver
Lorusso D, Raspagliesi F, Ronzulli D, Valabrega G, Colombo N, Pisano C, et al. Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial. Journal of Clinical Oncology. 2024;42(13):1488-1498. doi:10.1200/jco.23.01225
BibTeX
@article{Lorusso2024,
author = {Lorusso, Domenica and Raspagliesi, Francesco and Ronzulli, Dominique and Valabrega, Giorgio and Colombo, Nicoletta and Pisano, Carmela and Cassani, Chiara and Tognon, Germana and Tamberi, Stefano and Mangili, Giorgia and Mammoliti, Serafina and De Giorgi, Ugo and Greco, Filippo and Mosconi, Anna Maria and Breda, Enrico and Artioli, Grazia and Andreetta, Claudia and Casanova, Claudia and Ceccherini, Rita and Frassoldati, Antonio and Salutari, Vanda and Giolitto, Serena and Scambia, Giovanni},
title = {Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {13},
pages = {1488--1498},
doi = {10.1200/jco.23.01225}
}
EUVIMED